



(Incorporated in Singapore on 21 August 2014)  
(Company Registration Number: 201424579Z)

## **NEWS RELEASE – FOR IMMEDIATE RELEASE**

### **UG HEALTHCARE’S IPO ATTRACTS STRONG INVESTOR DEMAND**

- **Invitation approximately 11.50 times subscribed**
- **Trading to commence on the SGX-ST on Monday, 8 December 2014 at 9.00 a.m.**

**Singapore, 05 December 2014 – UG Healthcare Corporation Limited 优格医疗有限公司** (“**UG Healthcare**” or the “**Company**”, and together with its subsidiaries, the “**Group**”), an established Malaysia-based manufacturer and distributor of latex examination gloves, announced that it has received strong demand from both institutional and retail investors for its initial public offering (“**IPO**” or the “**Invitation**”) of 28,800,000 shares priced at S\$0.215 per share.

The Invitation comprises an offer of 1,800,000 shares to the public for subscription (the “**Public Offer**”) and a placement of 27,000,000 shares to investors (the “**Placement Tranche**”).

At the close of the Invitation at 12.00 p.m. on 4 December 2014, 2,468 valid applications were received for the Public Offer. These applicants applied for an aggregate 304,350,000 Offer Shares, with application monies received amounting to approximately S\$65.4 million. In addition, the Placement Tranche (which excludes 217,000 Placement Shares that were rejected due to multiple application, and were therefore made available to satisfy excess applications for Offer Shares) was fully subscribed, with application monies received amounting to approximately S\$5.8 million. Based on the total Invitation size of 28,800,000 shares and total valid applications received for 331,133,000 Invitation Shares, the Invitation was approximately 11.50 times subscribed.

UG Healthcare will be listed on the Catalist of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”) under the stock code 41A and trading of its shares is expected to commence at 9.00 a.m. on 8 December 2014.

**Mr. Lee Jun Yih, Executive Director of UG Healthcare said, “*We are pleased with the overwhelming investor demand for the IPO, which we believe attests to our strong fundamentals and investment merits. We would like to thank everyone for their support and will strive to grow our business further, riding on resilient demand for disposable gloves and rising hygiene and healthcare awareness globally, especially in the emerging markets.*”**

Of the net proceeds of approximately S\$4.22 million, the Group plans to utilise S\$3.20 million for expansion of production capacity, S\$0.65 million for expansion of sales and distribution network, S\$0.30 million for developing new products and engaging in research and development, and the balance of S\$0.07 million for general working capital.

Based on the issue price of S\$0.215 per share and post-Invitation share capital of 188,023,530 shares, the market capitalisation of UG Healthcare is approximately S\$40.4 million.

~ End ~

**About UG HEALTHCARE CORPORATION LIMITED (SGX STOCK CODE: 41A)**

UG Healthcare Corporation Limited 优格医疗有限公司 (“**UG Healthcare**”) and together with its subsidiaries (the “**Group**”) is an established Malaysia-based glove manufacturer and distributor. Currently, the Group has two manufacturing facilities located in Seremban, Malaysia. To complement this manufacturing platform, it has established an extensive distribution network globally through its own distribution companies based in the USA, UK, Germany, the PRC and Nigeria, as well as through third party distributors.

Started in 1989, the Group has built its reputation as a reliable manufacturer and distributor of natural latex and nitrile examination gloves under its own brand names including its “Unigloves” brand name as well as third party labels where it is engaged as original equipment manufacturer. UG Healthcare also distributes ancillary products such as surgical, vinyl and cleanroom gloves, face masks and other medical disposables.

The Group’s competitive edge lies in its successful integration of its manufacturing and distribution businesses. The integrated platforms allow the Group to have full control over the entire supply chain, including (1) the production process, where it can carry out stringent quality control checks at every stage to ensure consistent product quality and compliance with various stringent international standards, as well as (2) the distribution of its products to end-users and intermediaries. With its own facilities, the Group is also able to customise products to meet the evolving requirements of customers in a cost effective manner.

Its products are sold to more than 50 countries including Germany, Nigeria, the PRC, USA, UK, France, Italy, Austria, Switzerland, the Netherlands, Japan, South Korea, Canada and Brazil.

For more information, please visit UG Healthcare’s website at [www.ughealthcarecorporation.com](http://www.ughealthcarecorporation.com)

---

***For Media and Analysts, please contact***

**WATERBROOKS CONSULTANTS PTE LTD**

Tel: (+65) 6100 2228

Ms Rosalina Soh / Ms Lynette Tan

(M): +65 9677 6683 / +65 9687 2023

(E): [rosalina@waterbrooks.com.sg](mailto:rosalina@waterbrooks.com.sg) / [lynette@waterbrooks.com.sg](mailto:lynette@waterbrooks.com.sg)

---

**IMPORTANT NOTICE**

This news release and any accompanying materials (if any) (the “**News Release**”) is for information purposes only, without regard to the objectives, financial situation or needs of any specific persons. Accordingly, no reliance whatsoever should be placed upon the information set out herein.

This News Release does not purport to be complete and is qualified in its entirety by, and should be read in conjunction with, the full text of the offer document of UG Healthcare Corporation Limited dated 28 November 2014 (the “**Offer Document**”) that has been registered by the SGX-ST acting as agent on behalf of the Monetary Authority of Singapore, including but not limited to the sections entitled “Risk Factors” and “Cautionary Notes Regarding Forward-Looking Statements” of the Offer Document. The information contained in this News Release should not be relied on as any representation or warranty by UG Healthcare Corporation Limited.

This News Release includes forward-looking statements provided with respect to the anticipated future performance of UG Healthcare Corporation Limited. Such forward-looking statements reflect various assumptions of the management concerning the future performance of UG Healthcare Corporation Limited. Accordingly, there can be no assurance that such forward-looking statements will be realised. The actual results may vary from the anticipated results and such variation may be material. No representations or warranties are made as to the accuracy or reasonableness of such assumptions or the forward-looking statements based thereon.

---

This News Release has been prepared by the UG Healthcare Corporation Limited (the “**Company**”) and its contents have been reviewed by the Company's sponsor, SAC Capital Private Limited (the “**Sponsor**”), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the “**Exchange**”). The Sponsor has not independently verified the contents of this News Release.

This News Release has not been examined or approved by the Exchange. The Sponsor and the Exchange assume no responsibility for the contents of this News Release, including the correctness of any of the statements or opinions made or reports contained in this News Release.

The contact person for the Sponsor is Mr. Bernard Lim (Telephone: 65-6221 5590) at 1 Robinson Road, #21-02 AIA Tower, Singapore 048542.